Connect
Discussion
Comment receiving replies
Replies to "@whatthef - Yep, that's Pluvicto. PSMAddition was a trial specifically adding Pluvicto to ARPI. The recent..."
Prostate Cancer | Last Active: 2 days ago | Replies (21)
Comment receiving replies
@whatthef - Yep, that's Pluvicto. PSMAddition was a trial specifically adding Pluvicto to ARPI. The recent FDA approval your Dr is referring to (7/31/26) is for castrate sensitive patients. Pluvicto was already approved for castrate resistant disease.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01092-5/abstract
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/170879-fda-approves-pluvicto-for-psma-positive-metastatic-hormone-sensitive-prostate-cancer-mhspc.html
Replies to "@whatthef - Yep, that's Pluvicto. PSMAddition was a trial specifically adding Pluvicto to ARPI. The recent..."
Connect
As @mjp0512 cited "The PSMAddition trial demonstrated that adding Pluvicto (177Lu-PSMA-617) to standard hormone therapy (ADT plus an ARPI) significantly improves radiographic progression-free survival in patients with PSMA-positive metastatic hormone-sensitive prostate cancer." https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01092-5/abstract
There are several discussions in the group about Pluvicto, for example:
- Anyone on Pluvicto? Looking for a support team https://connect.mayoclinic.org/discussion/anyone-on-pluvicto/
- Can anyone share their experience with Pluvicto?https://connect.mayoclinic.org/discussion/can-anyone-share-their-experience-with-pluvicto/
See all: https://connect.mayoclinic.org/group/prostate-cancer/
@whatthef, did you decide to start Pluvicto (177Lu-PSMA-617)? How are you doing?